Better Therapeutics, Inc. (BTTX)
OTCMKTS: BTTX · Delayed Price · USD
0.0003
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market open
Better Therapeutics Employees
Better Therapeutics had 54 employees as of December 31, 2022. The number of employees increased by 10 or 22.73% compared to the previous year.
Employees
54
Change (1Y)
10
Growth (1Y)
22.73%
Revenue / Employee
n/a
Profits / Employee
-$584,685
Market Cap
16.36K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 54 | 10 | 22.73% |
| Dec 31, 2021 | 44 | 15 | 51.72% |
| Dec 31, 2020 | 29 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
| Danaher | 63,000 |
BTTX News
- 2 months ago - Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc. - Business Wire
- 4 months ago - Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Business Wire
- 4 months ago - Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers - Business Wire
- 5 months ago - Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Business Wire
- 5 months ago - Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 5 months ago - Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease - Business Wire
- 5 months ago - Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment - Business Wire
- 6 months ago - Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone - Business Wire